Dear Editor,

The translocation (9;12)(q34;p13) *ETV6/ABL1* rearrangement is a rare but recurrent chromosomal translocation associated with a variety of hematological malignancies, including CML, atypical CML, AML, and ALL \[[@B1]\]. The structure of the ETV6/ABL1 oncoprotein is similar to that of BCR/ABL1, and they initiate similar downstream pathways \[[@B2]\]. There are two *ETV6/ABL1* fusion isoforms: the type A isoform, which fuses *ETV6* exon 4 with *ABL1* exon 2; and the type B isoform, which fuses *ETV6* exon 5 with *ABL1* exon 2 \[[@B3], [@B4]\]. To date, 30 cases of *ETV6/ABL1* fusion have been reported \[[@B5], [@B6]\], and only one of these cases resulted in CML with positive *BCR/ABL1* rearrangement \[[@B7]\]. Herein, we report a rare case of CML with *ETV6/ABL1* rearrangement.

A 54-yr-old male was admitted with persistent leukocytosis. Complete blood counts showed a white blood cell count of 21.7×10^9^/L with 1% blasts, Hb of 126 g/L, and platelet count of 294×10^9^/L. Physical examination was unremarkable. Bone marrow (BM) analysis showed typical characteristics of CML ([Fig. 1A, B](#F1){ref-type="fig"}). Chromosomal analysis of the BM cells demonstrated a balanced t(9;12)(q34;p13) translocation, which was not the Philadelphia chromosome ([Fig. 1C](#F1){ref-type="fig"}). FISH analysis with probes for *BCR/ABL1* (Abbott Vysis, Des Plaines, IL, USA detected no fusion signal. However, reverse transcriptase (RT)-PCR analysis of the *BCR/ABL1* fusion transcripts yielded positive results; the reaction product was 700 bp long, indicating positive rearrangement and hence, presence of the P230 chimeric protein at the molecular level ([Fig. 1D](#F1){ref-type="fig"}).

To visualize the *ETV6/ABL1* fusion signal, we prepared a mixture of two commercially available, locus-specific identifiers: a *BCR/ABL1* dual color, dual fusion translocation probe, and an *ETV6/RUNX1* extra signal dual color translocation probe (Abbott Vysis) ([Fig. 1E, F](#F1){ref-type="fig"}). Metaphase and interphase FISH with the mixed *BCR/ABL1* and *ETV6/RUNX1* probes showed one yellow fusion signal at 9q34, which was derived from a green signal from *ETV6* and a red signal from *ABL1* ([Fig. 1G, H](#F1){ref-type="fig"}). RT-PCR analysis of the *ETV6/ABL1* fusion transcript was positive for the 1,141-bp product, indicating a type B fusion ([Fig. 1D](#F1){ref-type="fig"}). After diagnosis, the patient was transferred to another hospital, and therefore, follow-up BM examination was not possible.

*ETV6/ABL1* rearrangement has been reported to result in enhanced tyrosine kinase activity and neoplastic transformation \[[@B3], [@B8]\]. A total of 13 cases of *ETV6/ABL1*-positive or atypical CML have been reported to date ([Table 1](#T1){ref-type="table"}) \[[@B5], [@B7]\]. Among those cases, including the present case, two were *BCR/ABL1* fusion-positive and 11 were either unknown or negative for the *BCR/ABL1* fusion. Both *BCR/ABL1* fusion-positive cases presented with persistent leukocytosis, eosinophilia, and no splenomegaly. Their pathological findings were consistent with those for CML, but *BCR/ABL1* rearrangement was not confirmed by karyotyping or FISH. Only RT-PCR revealed the rearrangement, and the amplicon size was 504 bp \[[@B7]\] and 700 bp in the present case, respectively. Marked eosinophilia, which is a common characteristic of the *ETV6/ABL1* translocation \[[@B7]\], was also predominant. Although the pathogenesis of eosinophilia is not clearly understood, *ETV6* is known to play an active role in the commitment of hematopoietic myeloid precursors to eosinophilic differentiation \[[@B9]\].

Rare cases of CML are associated with a *BCR* breakpoint that is considerably more directed towards the 3\' end than the major breakpoint cluster region, which encodes a P230 *BCR/ABL1* fusion protein. Our patient had a novel-sized *BCR/ABL1* fusion transcript (700 bp), which is \~140 bp smaller than the typically observed micro *BCR/ABL1* (c3a3) amplicon size of 838 bp, suggesting in-frame deletion of an exon. Although the lack of the Philadelphia chromosome observed by karyotyping and FISH is unusual, it is possible that RT-PCR is more sensitive than cytogenetics or FISH. Unfortunately, Sanger sequencing of the identified novel transcript could not be performed, and 2 weeks later, a repeat RT-PCR analysis of the peripheral blood failed to detect any *BCR/ABL1* fusion transcripts.

Detection of the *ETV6/ABL1* fusion may help to inform treatment plans for patients with rare hematologic malignancies. In these cases, tyrosine kinase inhibitors can be effective because of the significant overlap between the molecular targets of *ETV6/ABL1* and those of *BCR/ABL1* \[[@B10]\].

In conclusion, we identified an *ETV6/ABL1* translocation in a patient with CML, which was confirmed by FISH with combined *BCR/ABL1* and *ETV6/RUNX1* probes, as well as by RT-PCR analysis. This report will contribute to a better understanding of the clinical phenotype and molecular basis of this rare type of *ETV6/ABL1*-positive hematologic malignancy.
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![Bone marrow (BM) aspiration, biopsy, karyotyping, reverse transcription (RT)-PCR, and FISH analyses of the present case. (A) BM aspiration (Wright-Giemsa stain, ×400) and (B) BM biopsy (hematoxylin & eosin stain, ×50) revealed 90% hypercellular marrow with a left-shifted neutrophilic series, an increased number of eosinophilic precursors, and small, hypolobated megakaryocytes. (C) Karyotyping showing t(9;12)(q34;p13); arrows indicate the translocated regions. (D) RT-PCR using *BCR/ABL1* and *ETV6/ABL1* primer pairs, revealing the 700-bp *BCR/ABL1* (lane 1, arrow) and 1,141-bp *ETV6/ABL1* (lane 2, arrow) fusion transcripts; left, 100-bp molecular weight marker ladder. The internal control 911-bp band is shown in lane 2. (E and F) FISH analysis using *BCR/ABL1* or *ETV6/RUNX1* probes, showing no abnormal signal. (G and H) FISH using the mixed *BCR/ABL1* and *ETV6/RUNX1* probes revealing one yellow fusion signal (*ABL1*, red; *ETV6*, green) on 9q34 analyzed in interphase (G) and metaphase (H) cells.](alm-37-77-g001){#F1}

###### Summary of patients with CML or atypical CML carrying the *ETV6/ABL1* fusion transcript

![](alm-37-77-i001)

                 Sex/Age (yr)   Splenomagaly   Initial CBC (WBC/Hb/Platelet)\*   Eosinophilia   Karyotype                             *BCR/ABL1* fusion (isoform)   *ETV6/ABL1* fusion isoform
  -------------- -------------- -------------- --------------------------------- -------------- ------------------------------------- ----------------------------- ----------------------------
  1              NA/49          NA             NA/NA/NA                          Yes            NA                                    NA                            Type B
  2              M/32           No             29/135/337                        Yes            46,XY,t(12;14)(p12;q11--13)           Negative                      Type B
  3              M/59           Yes            27/66/344                         Yes            46,XY,del(6)(p21),?t(9;12)(q34;p12)   NA                            Type A
  4              M/38           Yes            77.6/103/90                       NA             46,XY                                 NA                            Types A, B
  5              M/53           No             22/131/378                        Yes            46,XY                                 Negative                      Types A, B
  6              F/44           No             37/123/370                        Yes            46,XX,t(9;12)(q34;p13)                Positive (P210)               NA
  7              M/36           Yes            23.8/96/88                        Yes            45,XY,--7,t(9;12)(q34;q13)            NA                            Type B
  8              M/72           NA             57/98/32                          Yes            46,XY                                 NA                            NA
  9              F/24           Yes            98.8/113/261                      Yes            46,XX                                 Negative                      Type A
  10             M/79           NA             35.2/141/176                      Yes            46,XY                                 NA                            NA
  11             M/36           Yes            55/NA/NA                          No             46,XY,t(9;12)(q34;p13)                Negative                      NA
  12             F/52           NA             Increased/NA/Increased            Yes            46,XX,t(9;12)(q34;p13)                NA                            Types A, B
  Present case   M/54           No             21.7/126/294                      Yes            46,XY,t(9;12)(q34;p13)                Positive (P230)               Type B

Published cases were reviewed by Gancheva et al \[[@B5]\].

^\*^Values are presented in the International System of Units (WBC, ×10^9^/L; Hb, g/L; Platelet, ×10^9^/L).

Abbreviations: CBC, complete blood count; WBC, white blood cell; F, female; M, male; NA, not available; RT-PCR, reverse transcription PCR.
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